Primary Product

Beginning with cases diagnosed in January 1, 2024 and forward, the Cancer PathCHART initiative standards included in the 2024 Cancer PathCHART ICD-O-3 Site Morphology Validation List (CPC SMVL) should be used.

  • This list designates all tumor site-morphology combinations that are either valid or impossible as determined for sites reviewed by the Cancer PathCHART initiative.
  • For sites not reviewed for 2024, the existing standards from 2023 will remain unchanged in this list.
  • For cases diagnosed January 1, 2024, and later, the CPC SMVL will serve as the basis for the newly-added Primary Site, Morphology-Type, Beh ICDO3 2024 (N7040) edit, which checks for valid, unlikely and impossible site, histology, and behavior code combinations.

2024 Tumor Site-Morphology Standards

Implementation Timeline
review process

These tumor site-morphology combination standards will be updated annually, with the first updates implemented for cases diagnosed January 1, 2024, and later. In 2024, standards for approximately one-third of tumor sites will be updated by Cancer PathCHART. The remaining two-thirds of tumor sites will use 2023 standards. For cases diagnosed in 2025, approximately two-thirds of tumor sites will have site-morphology combination standards updated. For cases diagnosed 2026 and later, it is anticipated that all tumor sites will have site-morphology combination standards updated by Cancer PathCHART.

CPC*Search Tool

Magnifying Glass Search Icon

This Search Interface for 2024 allows for searches of histology and behavior codes, morphology terms, and tumor site combinations in the 2024 CPC SMVL.

Visit Now

Primary Sites Reviewed for 2024 Implementation

Organ System Primary Sites Reviewed for 2024 Implementation
Bone & Soft Tissue
  • Bones & Joints
  • Connective, Subcutaneous & Other Soft Tissue
  • Breast
  • Ampulla of Vater
  • Anus
  • Appendix
  • Biliary System
  • Colon & Rectum
  • Esophagus
  • Gallbladder
  • Liver
  • Pancreas
  • Small Intestine
  • Stomach
Female Genital
  • Cervix
  • Endometrium
  • Fallopian Tube
  • Myometrium
  • Ovary
  • Vagina
  • Vulva, Adnexa & Other Female Genital
  • Placenta
Male Genital
  • Penis
  • Prostate
  • Testis*
  • Kidney*

*For these primary sites, a subset of site-morphology combinations were reviewed for 2024 implementation, the remaining combinations will be reviewed for implementation with cases diagnosed 2025 and forward.